Acumen Pharmaceuticals, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
ABOS$0.24+6.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Changes in Stockholders’ Equity
(in thousands, except share data)
For the Three Months Ended March 31, 2025
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensive Income (Loss) · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2024 | 60,094,083 | $6 | $506,985 | $(325,127) | $(48) | $181,816 |
| Issuance of common stock for restricted stock units, net of shares withheld for taxes | 446,756 | — | (73) | — | — | (73) |
| Stock options exercised for cash | 32,586 | — | 37 | — | — | 37 |
| Unrealized gain on marketable securities | — | — | — | — | 63 | 63 |
| Stock-based compensation | — | — | 2,474 | — | — | 2,474 |
| Net loss | — | — | — | (28,796) | — | (28,796) |
| Balance as of March 31, 2025 | 60,573,425 | $6 | $509,423 | $(353,923) | $15 | $155,521 |
For the Three Months Ended March 31, 2024
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2023 | 57,910,461 | $6 | $489,453 | $(222,798) | $312 | $266,973 |
| Issuance of common stock for cash, net of issuance costs of $87 | 2,068,246 | — | 7,938 | — | — | 7,938 |
| Issuance of common stock for restricted stock units, net of shares withheld for taxes | 101,071 | — | (32) | — | — | (32) |
| Unrealized loss on marketable securities | — | — | — | — | (456) | (456) |
| Stock-based compensation | — | — | 2,484 | — | — | 2,484 |
| Net loss | — | — | — | (14,873) | — | (14,873) |
| Balance as of March 31, 2024 | 60,079,778 | $6 | $499,843 | $(237,671) | $(144) | $262,034 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.